These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 18359318

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
    Campia U, Matuskey LA, Panza JA.
    Circulation; 2006 Feb 14; 113(6):867-75. PubMed ID: 16461819
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec 14; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 7. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
    Werner C, Kamani CH, Gensch C, Böhm M, Laufs U.
    Diabetes; 2007 Oct 14; 56(10):2609-15. PubMed ID: 17623816
    [Abstract] [Full Text] [Related]

  • 8. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function.
    Risch L, Saely C, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H.
    Clin Chim Acta; 2007 Feb 14; 376(1-2):108-13. PubMed ID: 16956602
    [Abstract] [Full Text] [Related]

  • 9. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
    Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Mar 14; 26(3):624-30. PubMed ID: 16357312
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.
    Clin Endocrinol (Oxf); 2008 Sep 14; 69(3):452-61. PubMed ID: 18331610
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
    Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT.
    Am J Cardiol; 2006 Oct 15; 98(8):1057-62. PubMed ID: 17027571
    [Abstract] [Full Text] [Related]

  • 13. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis.
    Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M.
    Metabolism; 2008 Oct 15; 57(10):1414-21. PubMed ID: 18803947
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
    Pfützner A, Schöndorf T, Hanefeld M, Lübben G, Kann PH, Karagiannis E, Wilhelm B, Forst T.
    Horm Metab Res; 2009 Mar 15; 41(3):202-6. PubMed ID: 19224430
    [Abstract] [Full Text] [Related]

  • 18. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP, de Vries R, Sluiter WJ, Voorbij HA.
    Clin Endocrinol (Oxf); 2009 Feb 15; 70(2):221-6. PubMed ID: 18505467
    [Abstract] [Full Text] [Related]

  • 19. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY.
    Arthritis Res Ther; 2008 Feb 15; 10(1):R6. PubMed ID: 18199331
    [Abstract] [Full Text] [Related]

  • 20. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, Buchbinder S, Zorn M, Humpert PM, Hamann A, Morcos M, Nawroth PP, Bierhaus A.
    Horm Metab Res; 2007 Sep 15; 39(9):665-71. PubMed ID: 17846974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.